<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04834544</url>
  </required_header>
  <id_info>
    <org_study_id>IOV12</org_study_id>
    <nct_id>NCT04834544</nct_id>
  </id_info>
  <brief_title>A Study of Maintenance DCVAC/OvCa After First-line Chemotherapy Added Standard of Care</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled, Preliminary Verifying Study About Safety and Efficacy of Maintenance DCVAC/OvCa After First-line Chemotherapy Added to Standard of Care in Patients With Newly Diagnosed FIGO III-IV Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking University Third Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>SOTIO a.s.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Peking University Third Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, double-blind, placebo-controlled,parallel-group preliminary verifying&#xD;
      study about safety and efficacy of maintenance DCVAC/OvCa after first-line chemotherapy added&#xD;
      to standard of care in patients with newly diagnosed FIGO III-IV ovarian, fallopian tube, or&#xD;
      primary peritoneal carcinoma.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 19, 2021</start_date>
  <completion_date type="Anticipated">April 20, 2027</completion_date>
  <primary_completion_date type="Anticipated">October 20, 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progress Free Survival</measure>
    <time_frame>From randomization to the earlier date of assessment of objective progression or death by any cause in the absence of progression, the follow up period is about 2 years.</time_frame>
    <description>PFS defined as the time from randomization to the earlier date of assessment of objective progression or death by any cause in the absence of progression; progression will be assessed by the investigator per Response Evaluation Criteria In Solid Tumors (RECIST) 1.1</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">75</enrollment>
  <condition>Epithelial Ovarian Carcinoma</condition>
  <condition>Fallopian Tube Carcinoma</condition>
  <condition>Primary Peritoneal Carcinoma</condition>
  <arm_group>
    <arm_group_label>DCVAC/OvCa arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo arm</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>DCVAC/OvCa</intervention_name>
    <description>An active cellular immunotherapy product containing autologous dendritic cells that are generated ex vivo from patient's monocytes and apoptotic tumor cells prepared from tumor cell lines</description>
    <arm_group_label>DCVAC/OvCa arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Eighteen years of age or older at the time written informed consent is obtained&#xD;
&#xD;
          2. Newly diagnosed, histologically confirmed FIGO stage III or IV EOC (high-grade serous&#xD;
             or high-grade endometrioid)&#xD;
&#xD;
          3. After primary debulking surgery or after interval debulking surgery; residual disease&#xD;
             after surgery with optimal resection as R0 or R1 (R0 is defined as no macroscopic&#xD;
             residual disease, R1 is defined as macroscopic residual disease with a maximal&#xD;
             diameter of &lt;1 cm)&#xD;
&#xD;
          4. Known BRCA status; if BRCA mutation status not known, results of BRCA testing must be&#xD;
             available before randomization&#xD;
&#xD;
          5. Laboratory criteria:&#xD;
&#xD;
             5.1. White blood cells &gt;4000/mm3 (4.0×109/L) 5.2. Neutrophil count &gt;1500/mm3&#xD;
             (1.5×109/L) 5.3. Hemoglobin ≥8 g/dL (80 g/L) 5.4. Platelet count ≥100,000/mm3&#xD;
             (100×109/L) 5.5. Total bilirubin &lt;2× upper limit of normal (ULN) (benign hereditary&#xD;
             hyperbilirubinemias, e.g., Gilbert's syndrome, are permitted) 5.6. Serum alanine&#xD;
             aminotransferase, aspartate aminotransferase, and creatinine &lt;2×ULN 5.7. Blood urea&#xD;
             nitrogen &lt;2×ULN&#xD;
&#xD;
          6. Adequate coagulation parameters:&#xD;
&#xD;
             6.1. Activated partial thromboplastin time ≤1.5×ULN 6.2. International normalized&#xD;
             ratio ≤1.5&#xD;
&#xD;
          7. ECOG performance status 0-2&#xD;
&#xD;
          8. Patients of child-bearing potential and their partners who are sexually active must&#xD;
             agree to the use of 2 highly effective forms of contraception from the patient's&#xD;
             signing of the ICF until 6 months after the last/final dose of first-line Pt-based&#xD;
             adjuvant chemotherapy or IMP, whichever occurs later:&#xD;
&#xD;
             a. Condom with spermicide and one of the following:&#xD;
&#xD;
               -  Oral contraceptive or hormonal therapy (e.g., hormone implants)&#xD;
&#xD;
               -  Placement of an intra-uterine device (IUD)&#xD;
&#xD;
             Acceptable non-hormonal birth control methods include:&#xD;
&#xD;
               1. Total sexual abstinence from the patient's signing of the ICF until 6 months&#xD;
                  after the last/final dose of first-line Pt-based adjuvant chemotherapy or IMP,&#xD;
                  whichever occurs later&#xD;
&#xD;
               2. Vasectomized sexual partner plus male condom with spermicide and participant&#xD;
                  assurance that partner received post-vasectomy confirmation of azoospermia&#xD;
&#xD;
               3. Tubal occlusion plus male condom with spermicide&#xD;
&#xD;
               4. IUD plus male condom with spermicide. Provided coils are copper-banded.&#xD;
&#xD;
             Acceptable hormonal methods include:&#xD;
&#xD;
               1. Etonogestrel implants (e.g., Implanon, Norplan) plus male condom with spermicide&#xD;
&#xD;
               2. Normal and low dose combined oral pills plus male condom with spermicide&#xD;
&#xD;
               3. Norelgestromin/ethinyl estradiol transdermal system plus male condom with&#xD;
                  spermicide&#xD;
&#xD;
               4. Intravaginal device plus male condom with spermicide (e.g., ethinyl estradiol and&#xD;
                  etonogestrel)&#xD;
&#xD;
               5. Cerazette (desogestrel) plus male condom with spermicide. Cerazette is currently&#xD;
                  the only highly efficacious progesterone-based pill.&#xD;
&#xD;
          9. Signed informed consent and ability to comprehend its content&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Non-epithelial ovarian carcinoma or mixed epithelial histology&#xD;
&#xD;
          2. Borderline tumors (tumors of low malignant potential)&#xD;
&#xD;
          3. First-line Pt-based adjuvant chemotherapy already started after surgery&#xD;
&#xD;
          4. Intention to treat with intraperitoneal chemotherapy&#xD;
&#xD;
          5. Previous or concurrent radiotherapy to the abdomen and pelvis&#xD;
&#xD;
          6. Major surgery (with the exception of debulking surgery) within 3 weeks before informed&#xD;
             consent signature or patient has not recovered from any effects of any major surgery&#xD;
&#xD;
          7. Malignancy other than EOC, except malignancy that has been in complete remission for a&#xD;
             minimum of 3 years and except carcinoma in situ of the cervix or non-melanoma skin&#xD;
             carcinomas that have been definitively treated&#xD;
&#xD;
          8. Use of any immunotherapy in the past (e.g., anti-PD-1/PD-L1 or other immune checkpoint&#xD;
             inhibitors, therapeutic vaccines, adoptive cell therapy, cytokines); in case of&#xD;
             uncertainty, discuss with the medical monitor&#xD;
&#xD;
          9. Symptomatic uncontrolled brain or leptomeningeal metastases. A scan to confirm the&#xD;
             absence of brain metastases is not required. Patients with spinal cord compression may&#xD;
             be considered if they have received definitive treatment for this and evidence of&#xD;
             clinically stable disease for 28 days.&#xD;
&#xD;
         10. Co-morbidities:&#xD;
&#xD;
             10.1. HIV positive 10.2. Active hepatitis B (HBV) and/or C (HCV), active syphilis&#xD;
             10.3. Evidence of active bacterial, viral, or fungal infection requiring systemic&#xD;
             treatment 10.4. Clinically significant cardiovascular disease including: 10.4.1.&#xD;
             Symptomatic congestive heart failure 10.4.2. Unstable angina pectoris 10.4.3. Severe&#xD;
             cardiac arrhythmia requiring medication 10.4.4. Uncontrolled hypertension 10.4.5.&#xD;
             Myocardial infarction or ventricular arrhythmia or stroke within a 6-month period&#xD;
             before inclusion, ejection fraction &lt;40% or serious cardiac conduction system&#xD;
             disorders, if a pacemaker is not present 10.5. Pericardial effusion of any CTCAE grade&#xD;
             10.6. Severe chronic obstructive pulmonary disease defined as grade C and D according&#xD;
             to Global Initiative for Obstructive Lung Disease 10.7. Patients considered a poor&#xD;
             medical risk due to other serious, uncontrolled medical disorders, non-malignant&#xD;
             systemic diseases or active, uncontrolled infections 10.8. History or current evidence&#xD;
             of any condition, therapy, or laboratory abnormality that might confound the results&#xD;
             of the study, interfere with the patient's participation for the full duration of the&#xD;
             study treatment, or is not in the best interest of the patient to participate 10.9.&#xD;
             Active autoimmune disease requiring treatment 10.10. History of severe forms of&#xD;
             primary immune deficiencies 10.11. History of anaphylaxis or other severe reactions&#xD;
             following vaccination 10.12. Psychiatric or social conditions which, in the&#xD;
             investigator's opinion, would prevent participation in the study&#xD;
&#xD;
         11. Known hypersensitivity to any constituent of IMP&#xD;
&#xD;
         12. Systemic immunosuppressive therapy for any reason (except inhaled / intranasal&#xD;
             steroids and short-term systemic steroids &lt;30 days duration and ≤10 mg&#xD;
             prednisone-equivalent per day are allowed)&#xD;
&#xD;
         13. Participation in a clinical trial using experimental therapy within the last 4 weeks&#xD;
             before informed consent signature&#xD;
&#xD;
         14. Pregnant or breast feeding, or expecting to conceive children within the projected&#xD;
             duration of the study treatment&#xD;
&#xD;
         15. Refusal to sign informed consent&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Yuan LI, Master</last_name>
    <phone>+86 18610689868</phone>
    <email>yuanli@bjmu.edu.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Peking University Third Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100191</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yuan LI</last_name>
      <phone>+86 18610689868</phone>
      <email>yuanli@bjmu.edu.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>March 29, 2021</study_first_submitted>
  <study_first_submitted_qc>April 6, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 8, 2021</study_first_posted>
  <last_update_submitted>April 30, 2021</last_update_submitted>
  <last_update_submitted_qc>April 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Ovarian Epithelial</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

